AUROPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.5
| Stock Code | AUROPHARMA | Market Cap | 72,455 Cr. | Current Price | 1,248 ₹ | High / Low | 1,320 ₹ |
| Stock P/E | 33.8 | Book Value | 369 ₹ | Dividend Yield | 0.32 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,213 ₹ | DMA 200 | 1,177 ₹ |
| Chg in FII Hold | -0.26 % | Chg in DII Hold | 0.06 % | PAT Qtr | 595 Cr. | PAT Prev Qtr | 581 Cr. |
| RSI | 53.2 | MACD | 26.0 | Volume | 8,45,543 | Avg Vol 1Wk | 12,77,838 |
| Low price | 994 ₹ | High price | 1,320 ₹ | PEG Ratio | 7.92 | Debt to equity | 0.21 |
| 52w Index | 77.8 % | Qtr Profit Var | 26.0 % | EPS | 36.7 ₹ | Industry PE | 27.2 |
📊 Analysis: AUROPHARMA trades at ₹1,248, above both 50 DMA (₹1,213) and 200 DMA (₹1,177), showing medium-term strength. RSI at 53.2 indicates neutral momentum, while MACD (26.0) is positive, suggesting bullish sentiment. Intraday volume (8,45,543) is below the weekly average (12,77,838), showing moderate participation. The stock presents fair potential for intraday trading today.
💡 Optimal Buy Price: ₹1,235–₹1,245 if price sustains above support levels.
🎯 Profit Exit Levels: ₹1,270 (near-term resistance), ₹1,300 (upper resistance zone).
🛡️ Stop-Loss: ₹1,220 to protect against downside risk.
⏱️ If Already Holding: Consider exiting near ₹1,270–₹1,300 if momentum slows. If price falls below ₹1,220 with volume, exit immediately to avoid losses.
Positive
- Quarterly PAT improved to ₹595 Cr. from ₹581 Cr., showing earnings growth.
- Price trading above both 50 DMA and 200 DMA, confirming medium-term strength.
- EPS of ₹36.7 supports valuation stability.
- Dividend yield of 0.32% provides shareholder return.
Limitation
- ROCE (10.8%) and ROE (8.65%) are relatively weak compared to peers.
- High PEG ratio (7.92) suggests valuation is expensive relative to growth.
- Intraday volume lower than weekly average, limiting short-term momentum.
Company Negative News
- FII holdings decreased (-0.26%), showing reduced foreign investor confidence.
- Profitability ratios remain weak despite earnings growth.
Company Positive News
- Quarterly profit growth (+26%) highlights operational improvement.
- DII holdings increased (+0.06%), showing domestic support.
- Stock trading near 52-week highs, reflecting market optimism.
Industry
- Pharma sector remains defensive with steady demand outlook.
- Industry PE at 27.2 is lower than AUROPHARMA’s PE (33.8), showing premium valuation.
Conclusion
✅ AUROPHARMA shows moderate intraday potential today with positive MACD, neutral RSI, and price above key moving averages. Traders may consider entry around ₹1,235–₹1,245 with profit targets near ₹1,270–₹1,300. However, weak ROCE/ROE and reduced FII interest warrant caution. Intraday traders should remain disciplined with stop-loss at ₹1,220 to manage risk.